{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T12:38:39Z","timestamp":1764333519468,"version":"3.40.3"},"reference-count":97,"publisher":"Informa UK Limited","issue":"3","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Investigational Drugs"],"published-print":{"date-parts":[[2025,3,4]]},"DOI":"10.1080\/13543784.2025.2472240","type":"journal-article","created":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T04:33:36Z","timestamp":1740544416000},"page":"217-229","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":1,"title":["Ongoing phase 2 agents for multiple sclerosis: could we break the phase 3 trial deadlock?"],"prefix":"10.1080","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-4963-8392","authenticated-orcid":false,"given":"Silvia","family":"Susin-Calle","sequence":"first","affiliation":[{"name":"Hospital del Mar Research Institute and Pompeu Fabra University","place":["Barcelona, Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose Enrique","family":"Martinez-Rodriguez","sequence":"additional","affiliation":[{"name":"Hospital del Mar Research Institute and Pompeu Fabra University","place":["Barcelona, Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elvira","family":"Munteis","sequence":"additional","affiliation":[{"name":"Hospital del Mar Research Institute and Pompeu Fabra University","place":["Barcelona, Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pablo","family":"Villoslada","sequence":"additional","affiliation":[{"name":"Hospital del Mar Research Institute and Pompeu Fabra University","place":["Barcelona, Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2025,2,28]]},"reference":[{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurol.2015.10.006"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.1159\/000367614"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-020-01830-0"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.1177\/13524585231161494"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.20588"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(14)70264-9"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(24)00027-9"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000012690"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2024.105706"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000093"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.3390\/molecules26175227"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-018-0094-z"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000005118"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2018.12.005"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01791"},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2017.01.024"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.1177\/11795735211050712"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1231363100"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2309439"},{"key":"e_1_3_5_22_1","unstructured":"Media update: frexalimab new phase 2 data showed reduction of key biomarker of nerve cell damage in relapsing MS [Internet]. [cited 2024 Jul 11]. Available from: https:\/\/www.sanofi.com\/en\/media-room\/press-releases\/2024\/2024-06-28-15-30-00-2906026"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2024.106112"},{"volume-title":"Presented at the 38th Annual meeting of the Consortium of Multiple Sclerosis Centers (CMSC 2024) May 29 \u2013June 1","author":"Krieger S","key":"e_1_3_5_24_1","unstructured":"Krieger S, Vermersch P, Chitnis T, et al. Frexalimab in relapsing multiple sclerosis and non-relapsing secondary progressive multiple sclerosis: design of phase 3 FREXALT and FREVIVA trials. In: Presented at the 38th Annual meeting of the Consortium of Multiple Sclerosis Centers (CMSC 2024) May 29 \u2013June 1; Nashville, TN."},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.1177\/13524585221137502"},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.1177\/1352458517728812"},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102129"},{"key":"e_1_3_5_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.51574"},{"key":"e_1_3_5_29_1","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200208"},{"key":"e_1_3_5_30_1","unstructured":"Immunic reports positive interim data from phase 2 CALLIPER trial of vidofludimus calcium in progressive multiple sclerosis - immunic therapeutics [Internet]. [cited 2024 Oct 2]. Available from: https:\/\/imux.com\/immunic-reports-positive-interim-data-from-phase-2-calliper-trial-of-vidofludimus-calcium-in-progressive-multiple-sclerosis\/"},{"key":"e_1_3_5_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtauto.2020.100075"},{"key":"e_1_3_5_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.42652"},{"key":"e_1_3_5_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(23)00157-1"},{"key":"e_1_3_5_34_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.41.7.1047"},{"key":"e_1_3_5_35_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.956907"},{"key":"e_1_3_5_36_1","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200080"},{"key":"e_1_3_5_37_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-02017-5"},{"key":"e_1_3_5_38_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0737-3"},{"key":"e_1_3_5_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(23)00375-7"},{"key":"e_1_3_5_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.medj.2024.03.002"},{"key":"e_1_3_5_41_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1002716107"},{"key":"e_1_3_5_42_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3181d7d651"},{"key":"e_1_3_5_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cct.2016.08.009"},{"key":"e_1_3_5_44_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1803583"},{"key":"e_1_3_5_45_1","doi-asserted-by":"publisher","DOI":"10.1177\/13524585231204710"},{"key":"e_1_3_5_46_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000207551"},{"key":"e_1_3_5_47_1","doi-asserted-by":"publisher","DOI":"10.1177\/13524585231213164"},{"key":"e_1_3_5_48_1","doi-asserted-by":"publisher","DOI":"10.1177\/13524585231224702"},{"key":"e_1_3_5_49_1","unstructured":"Inc M. MediciNova announces results of subgroup analysis from the SPRINT-MS phase 2b trial of MN-166 (ibudilast) in progressive MS [internet]. GlobeNewswire News Room; 2019 [cited 2024 Oct 2]. Available from: https:\/\/www.globenewswire.com\/news-release\/2019\/04\/01\/1794764\/7767\/en\/MediciNova-Announces-Results-of-Subgroup-Analysis-from-the-SPRINT-MS-Phase-2b-Trial-of-MN-166-ibudilast-in-Progressive-MS.html"},{"key":"e_1_3_5_50_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13690"},{"key":"e_1_3_5_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2015.02.051"},{"key":"e_1_3_5_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.109112"},{"key":"e_1_3_5_53_1","doi-asserted-by":"publisher","DOI":"10.1177\/13524585241269219"},{"key":"e_1_3_5_54_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12264-015-1555-3"},{"key":"e_1_3_5_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32346-2"},{"key":"e_1_3_5_56_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11064-021-03465-0"},{"key":"e_1_3_5_57_1","doi-asserted-by":"publisher","DOI":"10.4103\/1673-5374.355749"},{"key":"e_1_3_5_58_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-019-00717-4"},{"key":"e_1_3_5_59_1","doi-asserted-by":"publisher","DOI":"10.2174\/0929867322666150812145035"},{"key":"e_1_3_5_60_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-32278-0"},{"key":"e_1_3_5_61_1","unstructured":"Oculis | oculis announces positive OCS-05 phase 2 ACUITY trial in acute optic neuritis met primary safety endpoint and key secondary efficacy endpoints opening development pathways as a potential first-in-class neuroprotective therapy [Internet]. [cited 2025 Jan 10]. Available from: https:\/\/investors.oculis.com\/news-releases\/news-release-details\/oculis-announces-positive-ocs-05-phase-2-acuity-trial-acute\/"},{"key":"e_1_3_5_62_1","doi-asserted-by":"publisher","DOI":"10.2196\/24356"},{"key":"e_1_3_5_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cct.2023.107333"},{"key":"e_1_3_5_64_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2217635120"},{"key":"e_1_3_5_65_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0235615"},{"key":"e_1_3_5_66_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3618"},{"key":"e_1_3_5_67_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2407974121"},{"key":"e_1_3_5_68_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2018.01.021"},{"key":"e_1_3_5_69_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-5728(02)00269-2"},{"key":"e_1_3_5_70_1","doi-asserted-by":"publisher","DOI":"10.1191\/1352458505ms1143oa"},{"key":"e_1_3_5_71_1","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000374"},{"key":"e_1_3_5_72_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctim.2018.09.006"},{"key":"e_1_3_5_73_1","unstructured":"Home [Internet]. Octopus trial. [cited 2024 Sep 5]. Available from: https:\/\/ms-octopus.mrcctu.ucl.ac.uk\/"},{"key":"e_1_3_5_74_1","unstructured":"ISRCTN - ISRCTN14048364: testing and comparing multiple drugs at once against the standard treatment for progressive multiple sclerosis treatment [Internet]. [cited 2024 Sep 5]. Available from: https:\/\/www.isrctn.com\/ISRCTN14048364"},{"key":"e_1_3_5_75_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainres.2023.148648"},{"key":"e_1_3_5_76_1","doi-asserted-by":"publisher","DOI":"10.3389\/fncel.2023.1254303"},{"key":"e_1_3_5_77_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41401-021-00759-5"},{"key":"e_1_3_5_78_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2015.4807"},{"key":"e_1_3_5_79_1","unstructured":"Evobrutinib Phase III | Merck [Internet]. [cited 2024 Oct 3]. Available from: https:\/\/www.merckgroup.com\/en\/news\/evobrutinib-phase-lll.html"},{"key":"e_1_3_5_80_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000208058"},{"key":"e_1_3_5_81_1","doi-asserted-by":"publisher","DOI":"10.1177\/13524585241234783"},{"key":"e_1_3_5_82_1","doi-asserted-by":"publisher","DOI":"10.1177\/17562864241233041"},{"key":"e_1_3_5_83_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(24)00328-4"},{"key":"e_1_3_5_84_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2023.104705"},{"key":"e_1_3_5_85_1","doi-asserted-by":"publisher","DOI":"10.3390\/medicina60091401"},{"key":"e_1_3_5_86_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(22)00009-6"},{"key":"e_1_3_5_87_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2020.102807"},{"key":"e_1_3_5_88_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000004683"},{"key":"e_1_3_5_89_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.47588"},{"key":"e_1_3_5_90_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000012752"},{"key":"e_1_3_5_91_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-010-5863-2"},{"key":"e_1_3_5_92_1","doi-asserted-by":"publisher","DOI":"10.1177\/1352458518819380"},{"key":"e_1_3_5_93_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-021-00616-3"},{"key":"e_1_3_5_94_1","doi-asserted-by":"publisher","DOI":"10.3390\/biom12020222"},{"key":"e_1_3_5_95_1","doi-asserted-by":"publisher","DOI":"10.3390\/medicina60071050"},{"key":"e_1_3_5_96_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-33158-8"},{"key":"e_1_3_5_97_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2022.5250"},{"key":"e_1_3_5_98_1","unstructured":"Press release: tolebrutinib meets primary endpoint in HERCULES phase 3 study the first and only to show reduction in disability accumulation in non-relapsing secondary progressive multiple sclerosis [Internet]. [cited 2024 Oct 3]. Available from: https:\/\/www.sanofi.com\/en\/media-room\/press-releases\/2024\/2024-09-02-05-00-00-2938875"},{"key":"e_1_3_5_99_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2023.3331"}],"container-title":["Expert Opinion on Investigational Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13543784.2025.2472240","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T09:11:56Z","timestamp":1743757916000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13543784.2025.2472240"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,28]]},"references-count":97,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3,4]]}},"alternative-id":["10.1080\/13543784.2025.2472240"],"URL":"https:\/\/doi.org\/10.1080\/13543784.2025.2472240","relation":{},"ISSN":["1354-3784","1744-7658"],"issn-type":[{"type":"print","value":"1354-3784"},{"type":"electronic","value":"1744-7658"}],"subject":[],"published":{"date-parts":[[2025,2,28]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieid20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieid20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2024-11-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-02-22","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-02-28","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}